Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

Size: px
Start display at page:

Download "Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder"

Transcription

1 Annals of Oncology : Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder C. N. Sternberg, V. Pansadoro, F. Calabro, L. Marini, A. van Rijn, P. De Carli, D. Giannarelli, A. Platania & A. Rossetti San Raffaele Scientific Institute, Rome, Italy Summary Background: The possibility of bladder preservation as well as the utility of neo-adjuvant chemotherapy for invasive bladder cancer are controversial issues. The purpose of this study was the evaluation of neo-adjuvant chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder. Patients and methods: Eighty-seven consecutive evaluable patients with T -T a N x M TCC of the bladder were treated with three cycles of neo-adjuvant chemotherapy. After three cycles of, patients had TURB alone, patients underwent partial cystectomy, and patients were to undergo radical cystectomy. Results: Forty (5%) patients weret at the TURB following. Thirty (%) patients who had chemotherapy and TURB alone are alive; at a median follow-up of 5+ months (8+-9+). Twenty-four (5%) have maintained an intact Introduction Cisplatin-containing combination chemotherapy has become the gold standard of treatment for patients with advanced, metastatic transitional cell carcinoma (TCC). For those patients who attain complete remission, long term survival may be achieved []. In patients with locally advanced muscle-invasive bladder cancer, neoadjuvant chemotherapy was designed to treat micrometastatic disease, present in up to 5% of patients at the time of diagnosis []. In selected patients bladder preservation can be achieved with the use of neo-adjuvant chemotherapy plus radiotherapy, partial cystectomy or transurethral resection of the bladder (TURB) [-5]. The objectives of this study were to assess the value of neo-adjuvant chemotherapy and the feasibility of bladder-sparing following in selected patients with localized tumors. Patients and methods From January 988 until June 99, 88 consecutive patients with muscle-invasive TCC of the bladder were entered onto the protocol. bladder. Of responding patients with monofocal lesions who underwent partial cystectomy, 8 patients (%) are alive with a functioning bladder, at a median follow-up of 8+ months (-+ months). At a follow-up of months ( + months), (%) patients in the radical cystectomy group are alive. In patients who had downstaging to T o or superficial disease, median follow-up is 55 months (- + months) and five-year survival is %. Patients who failed to respond (T or greater after chemotherapy), at a median follow-up of months (-+ months), had five-year survival of only 9%. Conclusions: Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials. Key words: bladder preservation, locally advanced bladder cancer, neo-adjuvant chemotherapy The median age was years and the Karnofsky performance status was uniformly good. According to the 99 UICCC TNM staging system, patients (%) were clinically T b, 9 were T a (%), were T (%), and 8 were T a (9%). All patients were N o by CT scan. Patient characteristics are illustrated in Table. Three cycles of neo-adjuvant chemotherapy were given [], Dose reductions are described in the toxicity section (see below). Prior to protocol entry, all patients underwent clinical staging which included a CT scan, urinary cytology, and transurethral resection of the bladder (TURB). After completion of three cycles of chemotherapy all patients were to undergo complete clinical re-staging (CT scan, cytology, and TURB). When necessary, patients were to undergo either partial or radical cystectomy within four weeks after completion of chemotherapy. Informed consent was obtained in all patients. Results After completion of chemotherapy, patients underwent TURB alone, patients underwent partial cystectomy, and patients were to undergo radical cystectomy. Only patients underwent radical cystectomy, because patient developed a deep venous thrombosis and was placed on anti-coagulant therapy. In Table the clinical stage prior to three cycles of and the clinical stage (TURB results) after Downloaded from at Pennsylvania State University on May 8,

2 Table. Patient characteristics. Evaluable Sex Male Female Age (in years) KPS T stage T T a T b T Prior intravesical therapy Cycles Table. Clinical restaging (TURB results) following neo-adjuvant chemotherapy. Clinical stage prior to n 9 Clinical stage after Total 8 Cis Abbreviation: Ref - patients who refused TURB after chemotherapy. Patients highlighted in 'italics' had reduction of two clinical stages at TURB after chemotherapy. chemotherapy are presented. Clinical downstaging was defined as reduction in stage of at least two clinical stages. This was observed in 8% of the patients who underwent TURB after. Forty patients (5%) became T o at the TURB after chemotherapy. Neo-adjuvant chemotherapy and TURB alone Forty-two patients attained a clinical CR, or had downstaging to superficial disease. These patients underwent TURB after chemotherapy, and did not undergo cystectomy. Thirteen of these patients were > years old (median age years, range -8 years), seven had cardiac disease, four had pulmonary disease, and three had diabetes. The clinical course of these patients is summarized in Table. Of these patients, 9 weret at the TURB, had T a, had CIS, had T ]5 T with rapid progression in bone, and refused TURB. Eighteen of the forty-two (%) patients have remained free of disease recurrence or progression (NED). In the 9 patients who were T o, superficial recurrence was observed in patients, and was successfully treated with BCG in 5 and cystectomy in. Ref Table. Neo-adjuvant and TURB alone: treatment outcome relative to clinical (TURB) response to. Post T stage ct ct, Refused All 9 NED Su- Invaperf sive 8 Mets. 9 Invasive + mets 9 Alive Dead Table Partial cystectomy: treatment outcome relative to pathologic response to. Post P stage pt, s PT, pt All NED Superf. Invasive Mets. " One patient died of other causes than cancer. Intact bladder Functional bladder Alive J 8 5 Dead Seventeen percent of patients in the TURB group had superficial recurrences, % invasive disease, % developed metastases and % had both invasive and metastatic disease. Thirty of the forty-two (%) patients are alive. Twenty-four (5%) have maintained an intact bladder. follow-up for this group is 5+ months (8+- 9+). Five-year survival for this group is 9%. Of the 9 patients who were T o, (9%) are alive, and 9 (8%) have an intact bladder. Neo-adjuvant chemotherapy and partial cystectomy Candidates for partial cystectomy after neo-adjuvant chemotherapy were those who: a) attained a ccr or significant cpr to neo-adjuvant chemotherapy; b) who had solitary lesions in favorable anatomical locations (dome and anterior lateral walls of the bladder); c) with no history of previous or recurrent infiltrative bladder cancer; d) no carcinoma in situ (CIS); and e) who have a good bladder capacity. Table describes patients with monofocal lesions who responded to chemotherapy, and underwent partial cystectomy. Fifteen percent had superficial recurrences, % invasive disease and 8% developed metastases. At a median follow-up of 8+ months (-+ months), eight patients (%) are still alive with a functioning bladder. Five-year survival is 9%. Neo-adjuvant chemotherapy and radical cystectomy Thirty-one patients underwent radical cystectomy. The clinical course of these patients is described in Table 5. Forty-seven percent of the patients have had metastatic Downloaded from at Pennsylvania State University on May 8,

3 Table 5. Radical cystectomy: treatment outcome relative to pathologic response to. Post P stage pt, s pt TE Total NED Mets. 5 Alive Dead a 5 5 a One patient died of lung cancer. In each group designated '+' there was one patient with positive lymph nodes (pt N,, pt N,, pt b N > pt N ). Table Outcome and survival in 8 evaluable patients treated with neo-adjuvant n NED Alive Five-year follow-up survival TURB alone 8(%) (%) 5+months 9% (8+-9+) Partial 8(%) 8(%) 8+months 9% cystectomy (-+) Radical 5(%) (%) months 5% cystectomy (-+) Total 8 (%) 58(%) +months % (-5+) a a The median follow-up of the alive patients is months (+- + months). and % are alive without evidence of disease. Twenty (%) patients are alive at a follow-up of months (-+ months). Five-year survival is 5%. Bladder preservation, outcome, and overall survival Table outlines the outcome and survival for all three patient groups. The median survival for all patients has not yet been reached, however, 58 of the 8 (%) are alive at a median follow-up of + months (-5+ months). Thirty-two of the eighty-seven patients (%) are alive with a functional bladder. Fifty-five patients were managed with conservative therapy (TURB alone or partial cystectomy). Thirtyeight (9%) of these conservatively managed patients are alive, thirty-two (58%) with a functional bladder. In patients who had downstaging to T o or superficial disease, median follow-up is 55 months (- + months). Survival at five years is %. Patients who failed to respond were those who had persistent muscleinvasive disease (T or greater) after chemotherapy. At a median follow-up of months (-+ months), fiveyear survival was only 9%. Table. Overall WHO toxicity (%). WBC Hemoglobin Platelets Mucositis Renal Pathologic staging compared to clinical staging Half of the patients in this study did not undergo pathologic staging. For those who had both TURB and pathologic confirmation after chemotherapy, there was a % difference in stage when comparing clinical and pathologic staging. These data are compatible with those in the literature []. Toxicity Toxicity in percentages according to the WHO scale is described in Table. No patients in this series had nadir sepsis or death due to chemotherapy. Alopecia was universal. Nephrotoxicity was not a serious problem in these patients with localized disease and a good performance status. Delays between the administration of cycles and were mainly due to hematological toxicity. The median period between cycle and was days (range -9 days). The median time period between cycle and was days with a range of to 5 days. Initially, growth factors were not routinely available. As the study progressed, growth factors were administered only to patients with neutropenia. Patients who experienced grade - neutropenia or leukopenia, were prophylactically treated with growth factors in subsequent cycles. Dose intensity ranged from %-% (median % of drugs administered). There were seven patients that had a dose reduction at the start of the protocol treatment, either due to concomitant medical problems, or age. Two patients were started at %, two at 5% and three at 8%. Toxicity among these patients was not remarkable except for one patient who experienced leukopenia grade and neutropenia grade. An additional four patients had a change in dosage after the administration of the first cycle. One of these patients had grade and leukopenia and neutropenia, respectively and had cycle at 8% and then cycle at % of the dose with growth factor support. Discussion Neo-adjuvant chemotherapy has been used in the treatment of several solid tumors. The major advantages to neo-adjuvant chemotherapy are the predictive information gained by evaluating the response to chemotherapy, and the potential for bladder preservation. The bladder Downloaded from at Pennsylvania State University on May 8,

4 tumor is an in vivo marker, which permits evaluation of response to chemotherapy. This may permit continuation of treatment to maximal response, or discontinuation of ineffective therapy. Response of micrometastases is presumed to reflect response in the primary lesion, although this has not been proven. The optimal time to treat micrometastases is when their volume is small []- In terms of survival, neo-adjuvant chemotherapy has not been shown to have a definite advantage in published randomized studies. The MRC/EORTC trial of neo-adjuvant CMV followed by either cystectomy, radiation, or both revealed only a 5.5% improvement in -year survival in patients given three cycles of neoadjuvant chemotherapy. survival in the chemotherapy group was months compared with.5 months for the no-chemotherapy group. This is the largest study in neo-adjuvant chemotherapy in bladder cancer, with participation of 9 patients from institutions in countries. Yet, the study was powered to demonstrate a % survival difference. For a 5.5% difference to be meaningful, 5 patients would have been required. A % decrease in the risk of locoregional disease or death with chemotherapy was observed. The pt rate was % with CMV and % without CMV. Chemotherapy demonstrated activity in the primary tumor and may have delayed loco-regional and metastatic progression [8]. The Nordic cystectomy trial is the only randomized trial which suggested an improvement in survival in a subset of patients treated with neo-adjuvant adriamycin and cisplatin. In this trial, patients with T a -T lesions, experienced a % difference in cancer-specific survival and a 5% difference in overall survival [9]. Results of the SWOG trial of neo-adjuvant followed by cystectomy should be available shortly. Although randomized trails have not definitely proven a survival advantage, response to chemotherapy is an important prognostic factor. In collected data on patients, treated in 8 centers with neo-adjuvant chemotherapy and radical or partial cystectomy, five-year survival was 5% for patients who had downstaging of the primary tumor to pt or superficial disease versus only % for those who had residual muscle-infiltrating disease (^ PT) []. These data are very similar to those presented in this paper. Newer molecular prognostic factors, such as p5, may be useful in selecting patients for chemotherapy in the future. Some authors have observed that TURB alone without chemotherapy may produce similar survival results to cystectomy in highly selected patients with T -T a tumors. In patients with superficial T muscle-infiltrating tumors, five-year survival may range between 5% and %. Patients with T tumors may survive %- % of the time. Herr reported on patients with T disease who underwent a second staging TURB. If the second TURB demonstrated clinical T o, patients were observed and did not undergo radical cystectomy. At a follow-up of 5. years (range -), of 5 (5%) patients were disease-free, although some did require repeat TURB and intravesical therapy []. More recently, Solsona reported results on patients with T -T a bladder tumors treated by radical TURB alone. For selected patients with repeat negative biopsies, the five- and -year cause-specific survival rates were 8% and 5%, with bladder preservation rates of8%and8%[]. Although partial cystectomy is still not routinely recommended for all patients with invasive bladder cancer, some investigators feel that neo-adjuvant chemotherapy plus partial cystectomy may be an alternative to radical cystectomy for some patients. Suitable patients may include selected patients with monofocal lesions, which respond to chemotherapy. Such an approach may offer local control equivalent to that attained by radical cystectomy, but longer follow-up is clearly needed prior to any definitive statements regarding its efficacy. In % of the patients in this study, the bladder was preserved. Patients who had T o at the restaging TURB have done exceptionally well, with a median survival that has not yet been reached. These results are similar to those attained by the Memorial group. Of surgical candidates who received neo-adjuvant, (5%) achieved T o status at the restaging TURB. Of patients who had either TURB alone or partial cystectomy, (%) are alive, which includes 5 (58%) with an intact bladder. The authors concluded that the majority of T o patients preserved their bladder for up to years, and that cystectomy salvaged most, but not all relapsing patients []. This paper supports the feasibility of a bladder sparing approach in patients selected on the basis of response to chemotherapy. Although, no firm conclusions can be drawn from non-randomized studies, candidates for neo-adjuvant chemotherapy and bladder preservation are those who respond to a well-performed TURB and to neo-adjuvant chemotherapy [, ]. It is not known whether or not immediate cystectomy could have saved the patients whose bladders were preserved but who subsequently develop metastases. Distant metastases generally appear at 8 to months, suggesting that they may have been undetected on initial presentation []. In addition, in our study metastatic disease occurred more frequently in the group who had radical cystectomy immediately following chemotherapy. Bladder preservation remains a controversial topic and radical cystectomy is still regarded as the gold standard of treatment for muscle-invasive bladder cancer. Bladder sparing in selected patients on the basis of response to neo-adjuvant chemotherapy is a feasible approach which must be confirmed in prospective randomized trials. Future research will also concentrate upon molecular markers which can determine prognosis and upon improving chemotherapy [5]. Downloaded from at Pennsylvania State University on May 8,

5 5 References. Sternberg CN, Yagoda A, Scher HI et al. for advanced transitional cell carcinoma of the urothehura: Efficacy, and patterns of response and. Cancer 989: : Scher H, Herr H, Sternberg C et al. Neo-adjuvant chemotherapy for invasive bladder cancer: Experience with the regimen. Br J Urol 989; : 5-.. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 998; (): Kachnic LA, Kaufman DS. Heney NM. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 99; 5 (): Sternberg CN, Arena MG, Calabresi F et al. Neo-adjuvant (methotrexate, vinblastine, adriamycin and cisplatin) for infiltrating transitional cell carcinoma of the urothelium. Cancer 99; (): Herr HW. Staging invasive bladder tumors. J Surg Oncol 99; 5: -.. Sternberg CN, Raghavan D, Ohi Y et al. Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: What are the effects on survival and prognosis? Int J Urol 995, (): International collaboration of trialists on behalf of the MRC Advanced Bladder Cancer Working Party, the EORTC-GU Group, the Australian Bladder Cancer Study Group et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. Lancet 999; 5: 5^*. 9. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy J Urol 99; 55: 9-.. Splinter TA. Scher HI. Denis L et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 99: : -8.. Herr H W. Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 98; 8: -.. Solsona E, Iborra I, Ricos JVet al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Longterm followup of a prospective study. J Urol 998; 59: Schultz PIC, Herr HW, Zhang Z. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients with with five years follow-up. J Clin Oncol 99; (): 9-.. Herr HW,Whitmore WFJr, Morse MJ et al. Neoadjuvant chemotherapy in invasive bladder cancer: The evolving role of surgery. J Urol 99; : Stein JP, Ginsberg DA, Grossfeld GD et al. Effect ofp WAF/ CP expression on tumor progression in bladder cancer. J Natl Cancer Inst 998; 9 (): -9. Received 9 May 999; accepted 9 August 999. Correspondence to: C. N. Sternberg, MD, FACP Department of Medical Oncology San Raffaele Scientific Institute 5, Via E. Chianesi Rome Italy sternbc@roma.hsr.it Downloaded from at Pennsylvania State University on May 8,

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Organ-sparing treatment of invasive transitional cell bladder carcinoma Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,

More information

Neodjuvant chemotherapy

Neodjuvant chemotherapy Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional

More information

Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University

Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.

BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template. 2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical

More information

Radical Cystectomy Often Too Late? Yes, But...

Radical Cystectomy Often Too Late? Yes, But... european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer

More information

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008 Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation

More information

Partial Cystectomy for Invasive Bladder Cancer

Partial Cystectomy for Invasive Bladder Cancer European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen

More information

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National

More information

symposium article introduction symposium article

symposium article introduction symposium article Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin

More information

When to Integrate Surgery for Metatstatic Urothelial Cancers

When to Integrate Surgery for Metatstatic Urothelial Cancers When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male

More information

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy

More information

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience

Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,

More information

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,

More information

european urology 55 (2009)

european urology 55 (2009) european urology 55 (2009) 911 921 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer

More information

1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013

1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013 Advances in Urology Volume 2013, Article ID 317190, 6 pages http://dx.doi.org/10.1155/2013/317190 Research Article Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Bladder-Sparing Treatment of Invasive Bladder Cancer

Bladder-Sparing Treatment of Invasive Bladder Cancer Several alternatives to radical cystectomy for muscle-invasive bladder cancer have been studied. None, however, are reliably superior to operative treatment. Sidi Bou Said,Tunisia, 1999. Courtesy of J.

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

UROTHELIAL CELL CANCER

UROTHELIAL CELL CANCER UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?

Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? DOI: 10.1093/annonc/mdf670 Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? C. N. Sternberg Medical Oncology, Vincenzo Pansadoro Foundation, Clinic Pio XI, Rome, Italy Introduction

More information

Staging and Grading Last Updated Friday, 14 November 2008

Staging and Grading Last Updated Friday, 14 November 2008 Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty

More information

Issues in the Management of High Risk Superficial Bladder Cancer

Issues in the Management of High Risk Superficial Bladder Cancer Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma

More information

1.0 Dr D Mitchell Final version issued

1.0 Dr D Mitchell Final version issued Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) clinical management guidelines for muscle invasive and advanced transitional cell carcinoma of bladder Dr Darren Mitchell Consultant Clinical

More information

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.

More information

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection

More information

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten

More information

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer - Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the

More information

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates

BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates 2181 Treatment Options for Muscle-invasive Urothelial Cancer for Patients Who Were Not Eligible for Cystectomy or Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Report

More information

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT

More information

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J. Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature William Julian, MD James J. Stark, MD, FACP Maryview Medical Center February 20, 2009 Dr. Julian to

More information

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy

More information

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES

Invasive Bladder Transitional Cell Carcinoma OBJECTIVES Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder

More information

Impact of Gemcitabine and Cisplatin with Radiotherapy in locally Advanced or Metastatic Transitional Cell Carcinoma of Urinary Bladder

Impact of Gemcitabine and Cisplatin with Radiotherapy in locally Advanced or Metastatic Transitional Cell Carcinoma of Urinary Bladder Impact of Gemcitabine and Cisplatin with Radiotherapy in locally Advanced or Metastatic Transitional Cell Carcinoma of Urinary Bladder J. A. Mallick, S. A. Ali, N. Siddiqui, A. Fareed Department of Oncology,

More information

Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer

Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer european urology 52 (2007) 1106 1114 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial

More information

Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer

Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer 75 Bladder-sparing, Combined-modality Approach for Muscle-invasive Bladder Cancer A Multi-institutional, Long-term Experience Sisto Perdona, MD 1 Riccardo Autorino, MD, PhD 2 Rocco Damiano, MD 3 Marco

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI

More information

Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with

Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Kensuke Bekku, Takashi Saika, Yasuyuki Kobayashi, Ryo Kioshimoto, Taiki

More information

Trimodality Therapy for Muscle Invasive Bladder Cancer

Trimodality Therapy for Muscle Invasive Bladder Cancer Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,

More information

Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital

Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London

Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London Chemo-radiotherapy in muscle invasive bladder cancer Dr Paula Wells St Bartholomew s Hospital London Overview Evidence base for cystectomy vs bladder preservation Chemo-radiotherapy vs radiotherapy alone

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

Clinical problems in advanced bladder cancer

Clinical problems in advanced bladder cancer Journal of BUON 9: 121-126, 2004 2004 Zerbinis Medical Publications. Printed in Greece. CONTINUING EDUCATION IN ONCOLOGY Clinical problems in advanced bladder cancer years [2]. It is appropriate to focus

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau

More information

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery

More information

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

More information

M-VAC (methotrexate, vinblastine, d Titlefor poor prognosis patients with ur dose intensity Author(s) HIBI, Hatsuki; OKAMURA, Kikuo; TAKA SHIMOJI, Toshio; MIYAKE, Koji Citation 泌尿器科紀要 (1997), 43(2): 89-96

More information

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction

More information

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary

More information

Genitourinary Cancer. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 2005;10: Matthew D.

Genitourinary Cancer. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 2005;10: Matthew D. This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer The Role of Taxanes in the Management of

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR

BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR Med. J. Malaysia Vol. 38. No. I March 1983. BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR ZAKRIYA MAHAMOOTH HUSSAIN AWANG SUMMARY

More information

Point-Counterpoint: Radiation & Bladder Cancer

Point-Counterpoint: Radiation & Bladder Cancer Radiation Plays a Major Role in Certain Stages of Bladder Cancer ~ David C. Beyer, MD Radiation Therapy; no role in management of bladder cancer Robert E. Donohue M.D. Denver VAMC University of Colorado

More information

A patient with recurrent bladder cancer presents with the following history:

A patient with recurrent bladder cancer presents with the following history: MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from

More information

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression

Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as a Spinal Cord Compression Case Study TheScientificWorldJOURNAL (2008) 8, 223 227 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2008.43 Transitional Cell Carcinoma of the Upper Ureter Metastatic to the Thoracic Spine Presenting as

More information

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.

5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney. Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme

More information

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder

Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Safini et al. 31 case Series report peer Reviewed open OPEN ACCESS Pure non-bilharzial squamous cell carcinoma: An unusual form of carcinoma of the bladder Fatima Safini, Hassan Jouhadi, Meriem Elbachiri,

More information

Breast cancer Can I still keep my breast?

Breast cancer Can I still keep my breast? Bladder Cancer Organ-Sparing Approaches SAMO Interdisciplinary Workshop on Urogenital Tumors September 15, 2012 Daniel R. Zwahlen, MD Radiation Oncology Breast cancer Can I still keep my breast? History

More information

Bladder Preservation Strategies for Muscle Invasive Bladder Cancer

Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology

More information

Phase II Trial of Neoadjuvant Gemcitabine and Cisplatin in Patients with Resectable Bladder Carcinoma

Phase II Trial of Neoadjuvant Gemcitabine and Cisplatin in Patients with Resectable Bladder Carcinoma Clinical Urology Gemcitabine and Cisplatin in Resectable Bladder Carcinoma International Braz J Urol Vol. (5): 668, September October, 27 Phase II Trial of Neoadjuvant Gemcitabine and Cisplatin in Patients

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney

More information

Neoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment of Muscle Invasive Bladder Cancer

Neoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment of Muscle Invasive Bladder Cancer Med. J. Cairo Univ., VoL 81, No. 2, March: 117-122, 2013 www.medicaljournalofcairouniversity.com Neoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

A Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer

More information

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014 Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer available at www.sciencedirect.com journal homepage: www.europeanurology.com Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Nadine Houédé a,b, *, Philippe Pourquier

More information

ROBOTIC VS OPEN RADICAL CYSTECTOMY

ROBOTIC VS OPEN RADICAL CYSTECTOMY ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to

More information

Original article. C. Shannon, C. Crombie, A. Brooks, H. Lau, M. Drummond & H. Gurney

Original article. C. Shannon, C. Crombie, A. Brooks, H. Lau, M. Drummond & H. Gurney Annals of Oncology : 97-9.. Kluwer Academic Publishers. Printed in the Netherlands. Original article Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment

More information

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate Dr. Tareq Salah Ahmed,MD,ESMO Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate 1 st Assiut Urology department conference,marsa Alam 3 rd February 2015 Bladder cancer

More information

Lymph node dissection: how much is enough?

Lymph node dissection: how much is enough? 1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive

More information

Chapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer

Chapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer Chapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer A. Bex J.A. Nieuwenhuijzen J.M. Kerst F. Pos H. van Boven W. Meinhardt S.

More information

Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths

More information

Oral Communications & Posters

Oral Communications & Posters Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica

More information

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals 6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy

More information

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,

More information

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer

Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

3.1 Investigations for Patients Presenting with Haematuria Table 1

3.1 Investigations for Patients Presenting with Haematuria Table 1 3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements

More information

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute

Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member

More information

Upper Egypt experience in bladder preservation using concurrent chemoradiotherapy

Upper Egypt experience in bladder preservation using concurrent chemoradiotherapy Maklad et al. International Archives of Medicine 2013, 6:21 ORIGINAL RESEARCH Open Access Upper Egypt experience in bladder preservation using concurrent chemoradiotherapy Ahmed M Maklad 1*, Elsayed M

More information

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility

Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,

More information

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer

More information

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy

More information

Appendix 4 Urology Care Pathways

Appendix 4 Urology Care Pathways Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable

More information

Citation International journal of urology (2. Right which has been published in final f

Citation International journal of urology (2.  Right which has been published in final f Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation

More information